Now showing items 1-2 of 2

    • Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors. 

      Wagner, AJ; Banerji, U; Mahipal, A; Somaiah, N; Hirsch, H; Fancourt, C; Johnson-Levonas, AO; Lam, R; Meister, AK; Russo, G; Knox, CD; Rose, S; Hong, DS (American Society of Clinical Oncology, 2017-04-20)
      Purpose To evaluate MK-8242 in patients with wild-type TP53 advanced solid tumors. Patients and Methods MK-8242 was administered orally twice a day on days 1 to 7 in 21-day cycles. The recommended phase II dose (RP2D) was ...
    • Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors. 

      Wagner, AJ; Banerji, U; Mahipal, A; Somaiah, N; Hirsch, H; Fancourt, C; Johnson-Levonas, AO; Lam, R; Meister, AK; Russo, G; Knox, CD; Rose, S; Hong, DS (2017-04-20)
      Purpose To evaluate MK-8242 in patients with wild-type TP53 advanced solid tumors. Patients and Methods MK-8242 was administered orally twice a day on days 1 to 7 in 21-day cycles. The recommended phase II dose (RP2D) was ...